ClinicalTrials.gg
CompletedNCT01010945Updated Nov 21, 2024

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

A Phase 1 interventional study of erlotinib and gemcitabine in Advanced Pancreatic Cancer, sponsored by OSI Pharmaceuticals. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by OSI Pharmaceuticals (part of Astellas Pharma Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing gemcitabine in Adenocarcinoma — 3 open to participants now, 4 under way, none of them phase 3. Gemcitabine · Adenocarcinoma.

Enrollment
15th of 21
19 · median 37
Started
2010
with 3 others
Phase 1
4 of 22
none open now
Registered
6th of 22
by date

Among the 22 studies testing gemcitabine in Adenocarcinoma, this one is the 15th largest by enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2010, is one of 4 in phase 1, and was the 6th registered.

Adenocarcinoma

620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

3 of the 22 studies testing gemcitabine in Adenocarcinoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing gemcitabine in Adenocarcinoma, or all of them as a file.
02

Study summary

This is a phase 1b study to evaluate the combination of gemcitabine and Tarceva (erlotinib) and nab-paclitaxel in patients with advanced pancreatic cancer.

Read the detailed description

This is a single-arm, phase 1b study to determine the maximum tolerated dose (MTD) of the combination of erlotinib (daily), gemcitabine (weekly), nab-paclitaxel (weekly) in patients with advanced pancreatic cancer.

03

Conditions studied

  • Advanced Pancreatic Cancer

Browse trials for

Keywords

  • erlotinib
  • nab-paclitaxel
  • gemcitabine
  • Adenocarcinoma
  • Advanced Pancreatic Cancer
  • Phase 1b
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) Performance Status (PS) 0-1
  • Predicted of >= 12 weeks
  • Previous surgery
  • or cytologically confirmed, measurable, locally advanced, unresectable or pancreatic adenocarcinoma
  • No prior therapy for pancreatic cancer
  • Adequate organ and marrow function

    • >= 1.5 x 10\^9/L
    • >= 100 x 10\^9/L
    • Total \<= institutional
    • (SGOT)/ALT(SGPT) \<= 2 x institutional upper limits of normal
    • Serum creatinine \<= 1.5 x upper limits of normal
  • Negative pregnancy test
  • Patient must agree not to smoke while on study

Exclusion criteria

Exclusion Criteria:

  • Significant history of cardiac disease unless the disease is well controlled
  • Active or uncontrolled infections or serious illness or medical conditions that could interfere with the patient's ongoing participation in study
  • History of any psychiatric condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide
  • History of smoking within the previous 14 days before enrollment or positive cotinine test at baseline
  • Pregnant or breast-feeding females
  • Symptomatic that are not stable, that require , that are potentially life-threatening, or that have required radiation within the last 14 days
  • History of allergic reactions attributed to compounds of similar chemical or biological composition to the study drugs
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    erlotinib, gemcitabine, nab-paclitaxel

    Patients receive the following treatment in 28-day cycles: 1) erlotinib: orally once daily from days 1 through 28 continuous dosing; 2) gemcitabine (following nab-paclitaxel): intravenously over 30 minutes on days 1, 8 and 15 every 28 days; and 3) nab-paclitaxel: intravenously over 30 minutes on days 1, 8 and 15 every 28 days.

    Drug: erlotinib · Drug: gemcitabine · Drug: nab-paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose

    Time frame: Monthly (to a maximum of 12 months)

Secondary outcomes

  1. Safety of drug combination assessed through dose limiting toxicities (DLTs)

    Time frame: 1 month

  2. Safety of drug combination assessed through Adverse Events (AEs)

    Time frame: Monthly (to a maximum of 12 months)

  3. Evaluate erlotinib Pharmacokinetic (PK) trough concentrations (C24h)

    Time frame: Days 29 (Cycle 2, Day 1) and 30

  4. Objective Response Rate

    Response will be based on the RECIST v1.1 criteria. Patients with partial and complete response will be classified as "responders".

    Time frame: Monthly (to a maximum of 12 months)

  5. Progression Free Survival (PFS)

    PFS will be calculated as the time from start of treatment until disease progression or death; patients who are still alive and free of progression at their last follow-up will be censored at that time.

    Time frame: Monthly (to a maximum of 12 months)

  6. Overall Survival

    Survival will be calculated as the time from start of treatment until death of any cause, patients who are still alive at their last follow-up will be censored at that time.

    Time frame: Monthly (to a maximum of 12 months)

07

Study locations

5 sites
  • Desert Comprehensive Cancer Center
    Palm Springs, California 92262, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27514, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Vanderbilt Ingram Cancer Center
    Nashville, Tennessee 37232, United States
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2010 to primary completion in Jan 2012, 23 months.

Of 50 phase 1 interventional studies under Adenocarcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 64. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2009
First posted
Nov 10, 2009
StartActual
Feb 3, 2010
Primary completionActual
Jan 25, 2012
CompletionActual
Jan 25, 2012
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01010945
Responsible party
Sponsor
First posted
Nov 10, 2009
Start date
Feb 3, 2010
Primary completion
Jan 25, 2012
Completion
Jan 25, 2012
Last update
Nov 21, 2024

Study contacts

Medical Monitor
study director · Astellas Pharma Global Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Erlotinib · Gemcitabine · Albumin-Bound Paclitaxel

Start the discussion